Latest Shareholder Approval News

New Age Exploration appoints seasoned geologist Kirby Johnson as CEO and acquires the promising Wallah Silver Project in NSW, complementing positive drilling results at its Wagyu Gold Project in Pilbara.

Kingfisher Mining has agreed to sell its Gascoyne rare earth elements project to Dreadnought Resources for $2 million in shares plus milestone payments, freeing capital to advance its copper-gold portfolio in New South Wales.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

Magellan Financial Group has announced a landmark merger with Barrenjoey Capital Partners, creating a diversified financial powerhouse valued at over A$1.6 billion. The deal includes a significant share placement and board reshuffle, setting the stage for expanded market influence.

MCS Services Limited has reported a significantly reduced half-year loss and announced plans to sell its Highways Traffic subsidiary, aiming to strengthen its financial position amid ongoing challenges.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Codeifai Limited reported a 26% revenue decline to $598,497 for 2025 alongside a sharp increase in net loss to $6.22 million, driven by strategic investments and market challenges. The company’s pivot to self-service SaaS platforms, including a key acquisition post-year-end, signals a transformative but uncertain path forward.

Keybridge Capital has posted a $6.14 million loss for the half-year ended 31 December 2024, driven by legacy governance issues and significant legal costs. A new board, appointed following court intervention, is now focused on stabilising the company and pursuing recovery actions.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

I Synergy Group Limited reported a 15.63% drop in revenue to AUD 0.81 million for FY2025, alongside a 21.5% increase in net loss to AUD 0.34 million, with auditors flagging going concern uncertainties.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Insignia Financial Ltd shareholders are invited to vote on a $4.80 per share acquisition scheme by Daintree BidCo, an entity backed by CC Capital Partners LLC and affiliates. The Federal Court has approved the Scheme Meeting and the distribution of the Scheme Booklet, which includes an Independent Expert’s Report supporting the fairness and reasonableness of the offer.